A market analysis by Zion Market Research shows that bisphosphonates will reach $14 billion in sales by 2021. This is, in part, due to an burgeoning aging population. These first-line agents currently make up about 48 percent of the total osteoporosis drugs market. As more patients are prescribed bisphosphonates, physicians will increasingly be faced with managing drug-related adverse events from mild to serious to common and rare. Learn more in this article.
Compston J, Cooper A, Cooper C, et al. UK clinical guideline for the prevention and treatment of osteoporosis. Arch Osteoporos 2017;12:43. https://www.ncbi.nlm.nih.gov/pubmed/28425085
Eleutherakis-Papaiakovou E, Bamias A. Antiresorptive treatment-associated ONJ. Abstract. Eur J Cancer Care (Engl). 2017;26(6). https://www.ncbi.nlm.nih.gov/pubmed/29063702
Fassio A, Bertoldo F, Idolazzi L, et al. Drug-induced osteonecrosis of the jaw: the state of the art. Abstract. Reumatismo 2017;69:9-15. https://www.ncbi.nlm.nih.gov/pubmed/28535616
Jagpal A, Saag KG. How to use bisphosphonates safely and optimally. Rheumatology (Oxford). 2018;57:1875-1876. https://www.ncbi.nlm.nih.gov/pubmed/29165674